Ascendis Pharma A/S
SWB:A71
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Ascendis Pharma A/S
SWB:A71
|
DK |
|
LogicMark Inc
OTC:LGMK
|
US |
|
Europris ASA
F:2RG
|
NO |
|
P
|
Pacific Biosciences of California Inc
F:P09
|
US |
|
Kingfisher PLC
LSE:KGF
|
UK |
|
Sparc AI Inc
F:5OV0
|
AU |
|
H
|
H2O Innovation Inc
PAR:ALHEO
|
CA |
|
Q
|
Quanta Services Inc
DUS:QAA
|
US |
|
M
|
Marsh & McLennan Companies Inc
DUS:MSN
|
US |
|
M
|
MagnaChip Semiconductor Corp
XBER:SMG
|
LU |
|
Turkcell Iletisim Hizmetleri AS
IST:TCELL.E
|
TR |
|
T
|
Turkcell Iletisim Hizmetleri AS
XBER:TUL1
|
TR |
|
Western Uranium & Vanadium Corp
OTC:WSTRF
|
CA |
|
Eaton Corporation PLC
MIL:1ETN
|
IE |
|
World Acceptance Corp
NASDAQ:WRLD
|
US |
|
G
|
Geo Group Inc
SWB:GEG
|
US |
Wall St Price Targets
A71 Price Targets Summary
Ascendis Pharma A/S
According to Wall Street analysts, the average 1-year price target for A71 is 262.81 EUR with a low forecast of 222.38 EUR and a high forecast of 320.59 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is A71's stock price target?
Price Target
262.81
EUR
According to Wall Street analysts, the average 1-year price target for A71 is 262.81 EUR with a low forecast of 222.38 EUR and a high forecast of 320.59 EUR.
What is the Revenue forecast for Ascendis Pharma A/S?
Projected CAGR
50%
Over the last 12 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 3 years is 50%.
What is the Gross Profit forecast for Ascendis Pharma A/S?
Projected CAGR
54%
The compound annual growth rate for Gross Profit over the next 3 years is 54%.
